METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) DRUGS MARKET ANALYSIS

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen staphylococcus aureus. Methicillin-resistant Staphylococcus aureus (MRSA) can be divided into two types based on the mode of infection; hospital-associated MRSA infection (HA-MRSA) and community-associated MRSA infections (CA-MRSA). This infection is mainly associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection. Various antibacterial agents such as vancomycin, daptomycin, ceftaroline fosamil, tetracycline, clindamycine, and tedizolid phosphate are available in the market for treatment of infections associated with MRSA.

The global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs is estimated to be valued at US$ 984.6 million in 2020 and is expected to exhibit a CAGR of 4.4% over the forecast period (2020-2027).

Figure 1. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Share (%) in Terms of Value, By Region, 2020

To learn more about this report, request sample copy

Increasing product launches and approvals are expected to drive the market growth over the forecast period 

Growing incidence of infections associated with Methicillin-resistant staphylococcus aureus (MRSA) pathogens is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant staphylococcus aureus (MRSA), which is expected to boost the Methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market. The drug is available in a once-daily intravenous and oral antibiotic. It is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including gram-positive, gram-negative, atypicals, and other drug-resistant strains.

Furthermore, adoption of inorganic growth strategies such as merger, acquisition, collaborations by key players is one of the key factors responsible for growth of the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market For instance, in March 2019, Melinta Therapeutics entered into an exclusive license, supply, and distribution agreement with Hikma Pharmaceuticals. The deal include distribution rights of Melinta’s intravenous and oral formulations of antibiotic Baxdela (delafloxacin), across Middle East and North Africa markets.

Figure 2. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Share (%), by Drug Class, 2020

To learn more about this report, request sample copy

Increasing number of pipeline products is expected to drive the market growth over the forecast period

Rising number of pipeline products for MRSA drugs is also a major factor that is expected to boost growth of the global Methicillin-resistant staphylococcus auresus (MRSA) drugs. For instance, in March 2017, Durata Therapeutics Inc. initiated phase 3 clinical trial study on dalbavancin to determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children caused by susceptible gram-positive organisms Methicillin-resistant strains of Staphylococcus aureus.

Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs – Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 45 million infected individuals worldwide as of October 30, 2020. Due to the increasing prevalence of COVID-19, key players operating in the Methicillin-resistant staphylococcus aureus (MRSA) drugs market are focusing on research and development of novel products to support and combat the effect of COVID-19. COVID-19 pandemic has impacted the global economy and in turn, the Methicillin-resistant staphylococcus aureus (MRSA) drugs market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the third quarter of 2020

Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Restraint

Patent expiration of currently existing MRSA drugs will lead to large revenue loss for key players due to introduction of low cost generic drugs. This is expected to have negative impact on Methicillin-resistant staphylococcus aureus drugs market growth. For instance, in December 2015, various key players such as Camber Pharmaceuticals, Mylan N.V., and Teva Pharmaceutical Industries Ltd. launched generic version of Zyvox (Linezolid) which is used to treat susceptible Gram-positive infections (for example, Staphylococcus and Streptococcus spp.). 

Moreover, declining patient burden, and product recalls to treat MRSA drugs of some major companies are some of the factors that are expected to hamper the market growth over the forecast period.

Key Players

Major players operating in the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.